Clinical Trials Directory

Trials / Unknown

UnknownNCT01956825

The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver

THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Meir Medical Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease (NAFLD).

Detailed description

The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease. the study is an interventional one in which 60 patients who by definition have non alcoholic fatty licer disease (NAFLD) are divided randomly (double blind) into 2 groups: group 1: "study group". receive a product (flavoured water) which contains L-CARNITINE an magnesium. group 2: control. receive placebo. regular water. Length of trial - 12 weeks. The patients will be followed on a weekly base and variuos parameters will be compared (weight, lipid profile, insulin resistance etc.). "fibrotest" will be used at the beginning of the trial and at the end (week 12) comparing the fat content before and after the treatment.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENT"slim water"

Timeline

Start date
2014-01-01
Primary completion
2014-04-01
Completion
2014-04-01
First posted
2013-10-08
Last updated
2013-10-08

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01956825. Inclusion in this directory is not an endorsement.